Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia
Completed
- Conditions
- Invasive Fungal InfectionAcute Leukemia
- Registration Number
- NCT02823132
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Brief Summary
The aim of this study is to investigate levels of a protein, mannose binding lectin, in patients with acute leukemia who develop or not an invasive fungal infection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 134
Inclusion Criteria
Not provided
Exclusion Criteria
- Patients who have received an bone marrow PSC allograft (as such patients have a risk of aspergillosis, which appears in most cases after medullar recovery; they will not be included in the study).
- Patients who have received an autologous PSC graf (as the duration of neutropenia is in most cases less than 10 days).
- Patients whose neutropenia, retrospectively assessed, lasted less than 10 days.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum level of Mannose Binding Lectin (MBL) in patients with acute leukemia 1st day of the period of aplasia
- Secondary Outcome Measures
Name Time Method Serum levels of MBL during an episode of aplasia for both groups of patients studied Every day except Saturday and Sunday for roughly 3 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of Mannose Binding Lectin (MBL) in predicting Invasive Fungal Infection (IFI) in acute leukemia patients undergoing chemotherapy?
How does MBL deficiency correlate with susceptibility to IFI in chemo-induced aplasia in acute leukemia patients?
Are there comparative studies on MBL levels as a biomarker for IFI versus other fungal infection biomarkers in acute leukemia?
What are the molecular mechanisms by which MBL influences immune response to fungal pathogens in leukemia patients?
What are the implications of MBL-based patient stratification for antifungal prophylaxis strategies in acute leukemia treatment?
Trial Locations
- Locations (1)
Centre Hospitalier Universitaire
🇫🇷Dijon, France
Centre Hospitalier Universitaire🇫🇷Dijon, France